Table of Contents:
  • Modified viruses as friends
  • Most licensed vaccines are live-attenuated viruses
  • Natural oncolytic properties of viruses
  • Preferential replication, efficient tumor access
  • Clinical trials with oncolytic viruses
  • Licensed therapeutics
  • Added oncolytic properties
  • Targeting: entry and post-entry
  • Arming strategies
  • Shielding from neutralizing antibodies
  • Monitoring oncolytic virus replication in tumors
  • From bench to clinic: the measles paradigm